Academic Press Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Neurodegenerative Disease Research and Commonalities with Metabolic Diseases (Volume ... Review of Neurobiology, Volume 154)

Product Description Metabolic Drivers and Bioenergetic Components of Neurodegenerative Disease summarizes recent developments in intervention trials in neurodegenerative diseases, particularly Alzheimer’s and Parkinson’s, as well as increasing evidence for the overlap between drivers of metabolic and neurodegenerative disease that impact mitochondrial function and bioenergetics, and subsequently cellular function and pathophysiology. Topics covered include Brain Glucose and Ketone Utilization in Brain Ageing and Neurodegenerative Diseases; the Mitochondrial Hypothesis: Dysfunction, Bioenergetic Defects, and the Metabolic Link to Alzheimer’s Disease; the Metabolic Impact on Neuroinflammation and Microglial Modulation in Neurodegenerative Diseases, the Impact of Circadian and Diurnal Rhythms on Cellular Metabolic Function and Neurodegenerative Diseases, and much more. Review Covers the latest evidence on the commonalities of neurodegenerative disorders and metabolic disease About the Author Grazyna Söderbom, PhD is founder of Klipspringer AB. She received her BSc 1st Class Hons in Pharmacology & Toxicology from King’s College, London and PhD in Neuroscience from the University of London. She spent one year of her undergraduate studies investigating the role of the AT2-receptor subtype at Ciba-Geigy under the tutelage of Dr Marc de Gasparo. As a Wellcome Trust PhD Scholar in Prof. Peter Jenner’s Neurodegenerative Research Group, Grazyna focused on the aetiology of Parkinson’s disease, specifically the relevance of antioxidant enzymes in the basal ganglia and Parkinson’s pathogenesis. After working as a Post-Doctoral Research Fellow at the Clinical Age Research Unit at King’s College Hospital, Grazyna joined Zeneca/AstraZeneca Pharmaceuticals, which included five years as Global Brand Manager in Cardiovascular Medicine in Sweden. She was involved in the global marketing and communications behind the antihypertensive Atacand® and the launch of Atacand Plus®. Having discovered a strong interest in strategic medical communications, Grazyna launched Klipspringer in 2013, which specializes in scientific, medical and strategic writing and consultation for Academia, Bio-Pharma and beyond. Grazyna is passionate about “all things science, especially neuroscience, and the effective sharing of scientific knowledge to all levels of audiences. She has published scientific research of her own and now supports others in their scientific and medical communications. Grazyna is particularly interested in the potential implications of the link between metabolic disease and neurodegenerative disorders. Russell Esterline, PhD is currently a VP Global Medicines Leader at AstraZeneca Pharmaceuticals leading the advancement of late stage metabolic products towards registration and approval and beyond. He received his B.S. in Chemistry from Juniata College and his PhD in Toxicology from Rutgers University/UMDNJ Joint Graduate Program in Toxicology. He completed his Post-Doctoral training at the Johns Hopkins School of Hygiene and Public Health. Both pre- and post-graduate research focused on the impact of toxicants on mitochondrial function. At AstraZeneca, Russell led the development of CRESTOR (rosuvastatin) through its LCM delivery stage (METEOR, CORONA, AURORA, JUPITER, SATURN clinical trials) and more recently led the development of FARXIGA (dapagliflozin) through global approval and launch. As the FARXIGA lead, Russell became interested in understanding the underlying mechanism(s) behind the unique SGLT2i-driven benefit in patients with type 2 diabetes and has published a novel theory describing the metabolic underpinning of this benefit. If correct, this theory may have implications beyond the proven benefits on the heart and kidney into the CNS, a possibility which is currently being pursued through collaborations with leading scientists in the field. Jan Oscarsson is MD, PhD in Physiology and Registered physician